Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Cash Flow
How CFOs Can Optimize Cash Flow: 4 Steps
Facing another year of rising costs, finance chiefs must push their companies to do more with less to enhance liquidity and improve profitability.
By
Junaid Samnani and Sanjay Purohit
| June 6, 2023
Read More
Resources
Reports
Reports
2023
2022
Featured
Cash Flow
How CFOs Can Optimize Cash Flow: 4 Steps
Facing another year of rising costs, finance chiefs must push their companies to do more with less to enhance liquidity and improve profitability.
By
Junaid Samnani and Sanjay Purohit
| June 6, 2023
Read More
Sign Up
Menu
Reports
2023
2022
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
Sign Up
Sponsored by
EpiPen
Risk & Compliance
Mylan Settles Charges With SEC
Regulators said the pharmaceutical company failed to make disclosures around the DOJ’s investigation of its EpiPen.
By
Lauren Muskett
| September 27, 2019
Read More
M&A
Pfizer and Mylan to Combine Off-Patent Drugs Businesses
The combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, could draw annual sales of more than $20 billion.
By
Lauren Muskett
| July 29, 2019
Read More
Risk & Compliance
Mylan Underpaid U.S. on Rebates for EpiPen
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
By
Matthew Heller
| October 6, 2016
Read More
Risk
Mylan to Pay 92% Premium for Sweden’s Meda
After a relentless pursuit, pharmaceutical firm Mylan pays a large premium to acquire a company that sells over-the-counter drugs.
By
Matthew Heller
| February 11, 2016
Read More